undamentalytics Newsletter
Sign in

Korro Bio, Inc. income statement

In fiscal 2025, Korro Bio, Inc. reported revenue of $6.4m, up 181.5% on the year before, operating income of −$122m (a -1906.4% margin) and net income of −$117m, or −$12.48 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue29371400262
Research and development1937614257646651
General and administrative1527371727312827
Operating income−21−28−84−59−85−92−122−110
Interest expense—011————
Net interest income2——−00———
Income before tax−19−26−85−58−81−83−117−106
Income tax00000011
Net income−19−27−85−58−81−84−117−107
Diluted EPS−$114.50−$0.82−$123.50−$227.42−$53.08−$9.37−$12.48−$8.88
Diluted shares (average)————2m9m9m12m
EBITDA−20−26−81−56−81−88−118−108

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: CLGN vs KRROKRRO vs VTGNKRRO vs KRSA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Korro Bio, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Korro Bio, Inc.